The primary outcomes of IVC group and IVR group
| IVC group | IVR group | T | χ2 | P value | |
| Recurrent eyes/patient | 10/5 | 14/7 | / | 0.83 | 0.36 |
| Recurrence rate | 16.67% | 23.34% | / | / | / |
| PMA at initial treatment in recurrent infant (w) | 34.60±3.47 | 35.14±1.76 | −0.36 | / | 0.728 |
| PMA at second treatment in recurrent infant (w) | 43.31±3.85 | 43.43±3.89 | −0.05 | / | 0.961 |
| Interval between two treatment(w) | 8.71±6.62 | 8.29±2.56 | 0.16 | / | 0.878 |
IVC, intravitreal injection of conbercept; IVR, intravitreal injection of ranibizumab; PMA, postmenstrual age.